Despite dementia with Lewy bodies (DLB) being the second most common form of neurodegenerative dementia, more than 80% of DLB cases are initially misdiagnosed. Alpha-synuclein (a-syn) and tau species have been detected in peripheral tissues and biological fluids of DLB patients and among different biological fluids, saliva represent an easely accessible and non-invasive source for biomarker detection.
Objective
This study aimed to investigate salivary a-syn and tau species as molecular disease biomarkers, assessing their potential in the diagnosis of DLB and in the differential diagnosis on respect to Alzheimer's disease (AD) and Parkinson's disease (PD).
Methods
We measured total and oligomeric a-syn, total-tau, and S199-phosphorylated-tau (pS199-tau) in the saliva of 21 DLB, 20 AD, 20 PD patients, and 20 healthy subjects (HS) using quantitative enzyme-linked immunosorbent assay (ELISA) analyses.
Results
Salivary total a-syn was not significantly changed between the different groups, whereas all pathological groups had a higher oligomeric a-syn concentration than HS. Salivary total-tau concentration was higher in all the pathological groups than HS, whereas the concentrations did not differ among patients’ groups. Conversely, salivary levels of pS199-tau was higher in DLB and AD patients than in HS and PD patients. Both correlation matrix and principal component analysis showed that core clinical DLB features were related to a-syn pathology, while cognitive decline was associated with salivary levels of pS199-tau in both DLB and AD patients. Receiver operating characteristic analysis reported high diagnostic accuracy for both a-syn oligomers and pS199-tau, between DLB and HS, and an adequate accuracy between DLB and PD. Conversely, the diagnostic accuracy was not optimal between DLB patients and AD patients.
Conclusions
These findings provide preliminary evidence that salivary a-syn and tau species might be promising in identifying DLB patients on respect to PD patients and HS, while the diagnostic potential is limited on respect to AD.
van SteenovenIMajbourNKVaikathNN, et al.α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with Lewy bodies. Mov Disord2018; 33: 1724–1733.
2.
KaneJPMSurendranathanABentleyA, et al.Clinical prevalence of Lewy body dementia. Alzheimers Res Ther2018; 10: 19.
3.
LopezOLKullerLH. Epidemiology of aging and associated cognitive disorders: prevalence and incidence of Alzheimer’s disease and other dementias. Handb Clin Neurol2019; 167: 139–148.
4.
ZaccaiJMcCrackenCBrayneC. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing2005; 34: 561–566.
5.
MuellerCBallardCCorbettA,et al.The prognosis of dementia with Lewy bodies. Lancet Neurol2017; 16: 390–398.
6.
PrinceMBryceRAlbaneseE, et al.The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement2013; 9: 63–75.e2.
7.
McKeithIGBoeveBFDicksonDW, et al.Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology2017; 89: 88–100.
8.
SavicaRGrossardtBRBowerJH, et al.Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol2013; 70: 1396–1402.
9.
DonaghyPCMcKeithIG. The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res Ther2014; 6: 46.
10.
D’antonioFKaneJPMIbañezA, et al.Dementia with Lewy bodies research consortia: a global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group. Alzheimers Dement (Amst)2021; 13: e12235.
11.
GalvinJE. Improving the clinical detection of Lewy body dementia with the Lewy body composite risk score. Alzheimers Dement (Amst)2015; 1: 316–324.
12.
TaylorJPMcKeithIGBurnDJ, et al.New evidence on the management of Lewy body dementia. Lancet Neurol2020; 19: 157–169.
13.
SpillantiniMGCrowtherRAJakesR, et al.alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A1998; 95: 6469–6473.
14.
JellingerKAKorczynAD. Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?BMC Med2018; 16: 34.
15.
WalkerLStefanisLAttemsJ. Clinical and neuropathological differences between Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies - current issues and future directions. J Neurochem2019; 150: 467–474.
16.
IrwinDJXieSXCoughlinD, et al.CSF Tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. Neurology2018; 90: e1038–e1046.
17.
KonTTomiyamaMWakabayashiK. Neuropathology of Lewy body disease: clinicopathological crosstalk between typical and atypical cases. Neuropathology2020; 40: 30–39.
18.
HymanBTPhelpsCHBeachTG, et al.National Institute on Aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement2012; 8: 1–13.
19.
TannerJAIaccarinoLEdwardsL, et al.Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer’s disease. Brain2022; 145: 4489–4505.
20.
ShiMTangLToledoJB, et al.Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer’s disease. Alzheimers Dement2018; 14: 1052–1062.
21.
KovacsGGMilenkovicIWöhrerA, et al.Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol2013; 126: 365–384.
22.
MikolaenkoIPletnikovaOKawasCH, et al.Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol2005; 64: 156–162.
23.
RahimiJKovacsGG. Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther2014; 6: 82.
24.
NelsonPTJichaGAKryscioRJ, et al.Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol2010; 257: 359–366.
25.
Van SteenovenIAarslandDWeintraubD, et al.Cerebrospinal fluid Alzheimer’s disease biomarkers across the Spectrum of Lewy body diseases: results from a large multicenter cohort. J Alzheimers Dis2016; 54: 287–295.
26.
IngelssonM. Alpha-synuclein oligomers-neurotoxic molecules in Parkinson’s disease and other Lewy body disorders. Front Neurosci2016; 10: 408.
27.
KapakiEParaskevasGPEmmanouilidouE,et al.The diagnostic value of CSF α-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer’s disease. PLoS One2013; 8: e81654.
28.
MavroudisIPetridisFKazisD. Cerebrospinal fluid, imaging, and physiological biomarkers in dementia with Lewy bodies. Am J Alzheimers Dis Other Demen2019; 34: 421–432.
29.
BargarCWangWGunzlerSA, et al.Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson’s disease and dementia with Lewy bodies. Acta Neuropathol Commun2021; 9: 62.
30.
RossiMCandeliseNBaiardiS, et al.Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol2020; 140: 49–62.
31.
TrediciKDHawkesCHGhebremedhinE,et al.Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta Neuropathol2010; 119: 703–713.
32.
KangWChenWYangQ, et al.Salivary total α-synuclein, oligomeric α-synuclein and SNCA variants in Parkinson’s disease patients. Sci Rep2016; 6: 28143.
33.
De BartoloMIVivacquaGBelvisiD, et al.A combined panel of salivary biomarkers in de novo Parkinson’s disease. Ann Neurol2023; 93: 446–459.
34.
ShiMSuiYTPeskindER, et al.Salivary tau species are potential biomarkers of Alzheimer’s disease. J Alzheimers Dis2011; 27: 299–305.
35.
SanlucaCSpagnoloPMancinelliR, et al.Interaction between α-synuclein and bioactive lipids: neurodegeneration, disease biomarkers and emerging therapies. Metabolites2024; 14: 352.
36.
JiaoLLDongHLLiuMM, et al.The potential roles of salivary biomarkers in neurodegenerative diseases. Neurobiol Dis2024; 193: 106442.
37.
LuanMSunYChenJ, et al.Diagnostic value of salivary real-time quaking-induced conversion in Parkinson’s disease and multiple system atrophy. Mov Disord2022; 37: 1059–1063.
38.
VivacquaGMasonMDe BartoloMI, et al.Salivary α-synuclein RT-QuIC correlates with disease severity in de novo Parkinson’s disease. Mov Disord2023; 38: 153–155.
39.
MarksteinerJDefrancescoMHumpelC. Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease. Front Aging Neurosci2022; 14: 1014305.
40.
CuiYZhangHZhuJ, et al.Investigation of Whole and Glandular Saliva as a Biomarker for Alzheimer’s Disease Diagnosis. Brain Sci2022; 12: 595.
41.
WolginMZobernigMDvornykV, et al.Systematic review on Saliva biomarkers in patients diagnosed with Morbus Alzheimer and Morbus Parkinson. Biomedicines2022; 10: 1702.
42.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011; 7: 263–269.
43.
MosimannUPCollertonDDudleyR, et al.A semi-structured interview to assess visual hallucinations in older people. Int J Geriatr Psychiatry2008; 23: 712–718.
44.
DevicIHwangHEdgarJS, et al.Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson’s disease. Brain2011; 134(Pt 7): e178.
45.
PekelesHQureshiHYPaudelHK, et al.Development and validation of a salivary tau biomarker in Alzheimer’s disease. Alzheimers Dement (Amst)2018; 11: 53–60.
46.
SakashitaYMatsubaraTTakataT, et al.Lewy pathology of the submandibular gland in Lewy body disease: a report of autopsy cases. Neuropathology2021; 41: 476–483.
47.
DuggerBNWhitesideCMMaaroufCL, et al.The presence of select tau Species in human peripheral tissues and their relation to Alzheimer’s disease. J Alzheimers Dis2016; 51: 345–356.
48.
HamsafarYChenQBorowskyAD, et al.Biochemical analyses of tau and other neuronal markers in the submandibular gland and frontal cortex across stages of Alzheimer disease. Neurosci Lett2023; 810: 137330.
49.
GibbonsCHLevineTAdlerC, et al.Skin biopsy detection of phosphorylated α-synuclein in patients with synucleinopathies. JAMA2024; 331: 1298–1306.
50.
DonadioVIncensiARizzoG, et al.A new potential biomarker for dementia with Lewy bodies: skin nerve α-synuclein deposits. Neurology2017; 89: 318–326.
51.
CostanzoMGalosiEDe BartoloMI, et al.Evaluating the diagnostic potential of combined salivary and skin biomarkers in Parkinson’s disease. Int J Mol Sci2024; 25: 4823.
52.
GuYKociolekAFernandezKK, et al.Clinical trajectories at the End of life in autopsy-confirmed dementia patients with Alzheimer disease and Lewy bodies pathologies. Neurology2022; 98: E2140–E2149.
53.
FörstlH. The Lewy body variant of Alzheimer’s disease: clinical, pathophysiological and conceptual issues. Eur Arch Psychiatry Clin Neurosci1999; 249(Suppl 3): 64–67.
54.
KotzbauerPTTrojanowskiJQLeeVMY. Lewy body pathology in Alzheimer’s disease. J Mol Neurosci2001; 17: 225–232.
55.
Rodriguez-VieitezENielsenHM. Associations between APOE variants, tau and α-synuclein. Adv Exp Med Biol2019; 1184: 177–186.
56.
AntonellATort-MerinoARíosJ, et al.Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. Alzheimers Dement2020; 16: 262–272.
57.
BechSHjermindLESalvesenL, et al.Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat Disord2012; 18: 69–72.
58.
GuimarãesJCardosoMJSáMJ. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Mult Scler2006; 12: 354–356.
59.
BarthélemyNRLiYJoseph-MathurinN, et al.A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nat Med2020; 26: 398–407.
60.
AshtonNJIdeMSchöllM, et al.No association of salivary total tau concentration with Alzheimer’s disease. Neurobiol Aging2018; 70: 125–127.
61.
ChristensenKRCombsBRichardsC, et al.Phosphomimetics at Ser199/Ser202/Thr205 in tau impairs axonal transport in rat hippocampal neurons. Mol Neurobiol2023; 60: 3423–3438.
62.
WuHYKuoPCWangYT, et al.β-Amyloid induces pathology-related patterns of tau hyperphosphorylation at synaptic terminals. J Neuropathol Exp Neurol2018; 77: 814–826.
63.
MaurageCASergeantNRuchouxMM, et al.Phosphorylated serine 199 of microtubule-associated protein tau is a neuronal epitope abundantly expressed in youth and an early marker of tau pathology. Acta Neuropathol2003; 105: 89–97.
64.
ThomasAJHamiltonCAHeslegraveA, et al.A longitudinal study of plasma pTau181 in mild cognitive impairment with Lewy bodies and Alzheimer’s disease. Mov Disord2022; 37: 1495–1504.
65.
GibsonLLAbdelnourCChongJ, et al.Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers. Curr Opin Neurol2023; 36: 264–275.
66.
GonzalezMCAshtonNJGomesBF, et al.Association of plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia with Lewy bodies. JAMA Neurol2022; 79: 32–37.
67.
JacobsonSAMorshedTDuggerBN, et al.Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. Parkinsonism Relat Disord2014; 20: 1009–1014.
68.
FermanTJArvanitakisZFujishiroH, et al.Pathology and temporal onset of visual hallucinations, misperceptions and family misidentification distinguishes dementia with Lewy bodies from Alzheimer’s disease. Parkinsonism Relat Disord2013; 19: 227–231.
69.
NaasanGShdoSMRodriguezEM, et al.Psychosis in neurodegenerative disease: differential patterns of hallucination and delusion symptoms. Brain2021; 144: 999–1012.
70.
DuggerBNHoffmanBRScrogginsA, et al.Tau immunoreactivity in peripheral tissues of human aging and select tauopathies. Neurosci Lett2019; 696: 132–139.
71.
MiglisMGAdlerCHAntelmiE, et al.Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurol2021; 20: 671–684.
72.
KoeglspergerTRumpfSLSchließerP, et al.Neuropathology of incidental Lewy body & prodromal Parkinson’s disease. Mol Neurodegener2023; 18: 32.
73.
SchneiderJAArvanitakisZYuL, et al.Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain2012; 135: 3005–3014.
74.
MatarEShineJMHallidayGM,et al.Cognitive fluctuations in Lewy body dementia: towards a pathophysiological framework. Brain2020; 143: 31–46.
75.
HallidayGMHoltonJLReveszT,et al.Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol2011; 122: 187–204.
76.
BarbaLPaolini PaolettiFBellomoG, et al.Alpha and Beta synucleins: from pathophysiology to clinical application as biomarkers. Mov Disord2022; 37: 669–683.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
